Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back Reduces Chronic Graft-Versus-Host Disease and Results in Favourable Gvhd-Relapse Free Survival: 5-Year Follow-up of 107 Patients Treated in a Multicenter Study in Singapore

Blood (2022) 140 (Supplement 1): 4707–4708.

https://doi.org/10.1182/blood-2022-168995

Published: 2022

Journal Articles

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

Blood (2006) 108 (9): 2928–2936.

https://doi.org/10.1182/blood-2006-03-008706

Published: 2006

Journal Articles

Early and Sustained Response to Azacytidine in High-Risk MDS Patients with Monosomy 7 Correlates with Increased Apoptosis and Not CDKN2B Demethylation.

Kavita K. Raj, MD, Alison M. John, PhD, Aloysius Ho, MD, Nicholas Shaun B. Thomas, PhD, Ghulam J. Mufti, MD

Blood (2005) 106 (11): 2530.

https://doi.org/10.1182/blood.V106.11.2530.2530

Published: 2005

Journal Articles

Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Is as Effective in Poor Risk as Standard Risk Acute Myeloid Leukaemia (AML).

Wendy Ingram, Ziyi Lim, Antonio Pagliuca, Stephen Devereux, Aloysius Ho, Ghulam Mufti

Blood (2005) 106 (11): 2901.

https://doi.org/10.1182/blood.V106.11.2901.2901

Published: 2005

Journal Articles

Clonal Gammopathies Following Reduced Intensity Conditioning Transplantation with Fludarabine, Busulphan and Alemtuzumab for Myeloid Malignancies Predict Improved Overall Survival.

ZiYi Lim, Antonio Pagliuca, Wendy Ingram, Dragana Milojkovic, Mojtaba Akthari, Aloysius Ho, Stephen Devereux, Rafael Duarte, Ghulam J. Mufti

Blood (2005) 106 (11): 1410.

https://doi.org/10.1182/blood.V106.11.1410.1410

Published: 2005

Journal Articles

Improved Disease Free Survival Following Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Incorporating Alemtuzumab Compared with Autologous Stem Cell Transplantation in Follicular Lymphoma.

Wendy Ingram, Stephen Devereux, Juan Gonzalez, Aloysius Ho, Ghulam Mufti, Antonio Pagliuca

Blood (2005) 106 (11): 1144.

https://doi.org/10.1182/blood.V106.11.1144.1144

Published: 2005

Journal Articles

Use of Pre-Emptive Donor Lymphocyte Infusions To Achieve Durable Remission Following Alemtuzumab Based Reduced Intensity Conditioning (RIC) Transplantation for AML or MDS.

ZiYi Lim, Laurence Pearce, Wendy Ingram, Rafael Duarte, Stephen Devereux, Antonio Pagliuca, Aloysius Ho, Ghulam Mufti

Blood (2005) 106 (11): 1124.

https://doi.org/10.1182/blood.V106.11.1124.1124

Published: 2005

Journal Articles

Second Reduced Intensity Transplants Are Effective and Well Tolerated in Older Patients with Relapsed Myeloid Malignancies. A Single Centre Report.

Frederick E. Chen, MD, Humayun N. Ahmad, MD, Pritesh Junagade, MD, Zi Lim, Stephen Devereux, MD, Antonio Pagliuca, MD, Aloysius Ho, MD, Ghulam J. Mufti, MD

Blood (2005) 106 (11): 5406.

https://doi.org/10.1182/blood.V106.11.5406.5406

Published: 2005

Journal Articles

Matched Pair Analysis of Intravenous vs Oral Busulphan as Part of Fludarabine-Busulphan-Campath (Alemtuzumab) Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT).

ZiYi Lim, Dragana Milojkovic, Laurence Pearce, Michelle Kenyon, Aloysius Ho, Stephen Devereux, Antonio Pagliuca, Ghulam Mufti

Blood (2005) 106 (11): 1762.

https://doi.org/10.1182/blood.V106.11.1762.1762

Published: 2005

Journal Articles

Reduced Intensity Conditioned Volunteer Unrelated Donor Transplants Using Alemtuzumab Are Safe and Effective in Older Patients with Myelodysplastic Syndromes.

ZiYi Lim, Aloysius Ho, Michelle Kenyon, Stephen Devereux, Rafael Duarte, Antonio Pagliuca, Ghulam Mufti

Blood (2005) 106 (11): 444.

https://doi.org/10.1182/blood.V106.11.444.444

Published: 2005

Journal Articles

5-Azacytidine in the Treatment of High Risk Myelodysplastic Syndromes: Clinical Response Can Occur without Demethylation of the CDKN2B , CDKN1A or TP73 Gene Promoters.

Kavita Raj, MD, Alison John, PhD, Aloysius Ho, MD, Nicholas Shaun B. Thomas, PhD, Ghulam J. Mufti, MD

Blood (2004) 104 (11): 2369.

https://doi.org/10.1182/blood.V104.11.2369.2369

Published: 2004

Journal Articles

Single Centre Experience of Patients with Haematological Malignancies Admitted to Intensive Care Unit: A Comparative Review of Allogenic Bone Marrow Transplant Data.

Zi Yi Lim, Jane Graham, Sylvia Simpson, Stephen Devereux, Antonio Pagliuca, Aloysius Ho, G.J. Mufti

Blood (2004) 104 (11): 1830.

https://doi.org/10.1182/blood.V104.11.1830.1830

Published: 2004

Journal Articles

Clonal Gammopathies, Immune Cytopenias and Autoimmune Thyroid Dysfunction Following Alemtuzumab Containing Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

Mojtaba Akhtari, Kavita Raj, Wendy Ingram, Dragana Milojkovic, Ihab El-Hemaidi, Stephen Devereux, Antonio Pagliuca, Aloysius Ho, Ghulam Mufti

Blood (2004) 104 (11): 1839.

https://doi.org/10.1182/blood.V104.11.1839.1839

Published: 2004

Journal Articles

Gemtuzumab Ozogamicin with Donor Leucocyte Infusions Is Safe and Effective Therapy for a Subgroup of Relapsed Acute Myeloid Leukaemia and Myelodysplastic Syndrome Following Allogeneic Haemopoietic Stem Cell Transplantation (HSCT).

Kavita Raj, MD, Maadh Aldouri, MD, Aloysius Ho, MD, Antonio Pagliuca, MD, Stephen Devereux, MD, Ghulam Mufti, MD

Blood (2004) 104 (11): 1806.

https://doi.org/10.1182/blood.V104.11.1806.1806

Published: 2004

Journal Articles

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients

Rowena D. Faulkner, Charles Craddock, Jennifer L. Byrne, Prem Mahendra, Andrew P. Haynes, Hugh G. Prentice, Michael Potter, Antonio Pagliuca, Aloysius Ho, Stephen Devereux, Grant McQuaker, Ghulam Mufti, John Liu Yin, Nigel H. Russell

Blood (2004) 103 (2): 428–434.

https://doi.org/10.1182/blood-2003-05-1406

Published: 2004

NARROW

Early and Sustained Response to Azacytidine in High-Risk MDS Patients with Monosomy 7 Correlates with Increased Apoptosis and Not CDKN2B Demethylation.

Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Is as Effective in Poor Risk as Standard Risk Acute Myeloid Leukaemia (AML).

Clonal Gammopathies Following Reduced Intensity Conditioning Transplantation with Fludarabine, Busulphan and Alemtuzumab for Myeloid Malignancies Predict Improved Overall Survival.

Improved Disease Free Survival Following Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Incorporating Alemtuzumab Compared with Autologous Stem Cell Transplantation in Follicular Lymphoma.

Use of Pre-Emptive Donor Lymphocyte Infusions To Achieve Durable Remission Following Alemtuzumab Based Reduced Intensity Conditioning (RIC) Transplantation for AML or MDS.

Second Reduced Intensity Transplants Are Effective and Well Tolerated in Older Patients with Relapsed Myeloid Malignancies. A Single Centre Report.

Matched Pair Analysis of Intravenous vs Oral Busulphan as Part of Fludarabine-Busulphan-Campath (Alemtuzumab) Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT).

Reduced Intensity Conditioned Volunteer Unrelated Donor Transplants Using Alemtuzumab Are Safe and Effective in Older Patients with Myelodysplastic Syndromes.

5-Azacytidine in the Treatment of High Risk Myelodysplastic Syndromes: Clinical Response Can Occur without Demethylation of the CDKN2B , CDKN1A or TP73 Gene Promoters.

Single Centre Experience of Patients with Haematological Malignancies Admitted to Intensive Care Unit: A Comparative Review of Allogenic Bone Marrow Transplant Data.

Clonal Gammopathies, Immune Cytopenias and Autoimmune Thyroid Dysfunction Following Alemtuzumab Containing Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

Gemtuzumab Ozogamicin with Donor Leucocyte Infusions Is Safe and Effective Therapy for a Subgroup of Relapsed Acute Myeloid Leukaemia and Myelodysplastic Syndrome Following Allogeneic Haemopoietic Stem Cell Transplantation (HSCT).

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only